ADVOCATE. CONNECT. INNOVATE.

Bulletin, Institute

CARB-X Updates

October 2017

Read the latest of CARB-X:

  • CARB-X awarded its 20th project yesterday, funding Amicrobe to develop  a new bioengineered antimicrobial designed for direct application to contaminated and infected tissues Read More
  • Powered By CARB-X company Microbiotix and the AMR Centre announce co-development agreement targeting drug resistant P.aeruginosa in critically ill pneumonia patients Read More
  • Powered By CARB-X company Achaogen awarded up to $18 million contract by BARDA to support development of orally-administered antibacterial candidate C-Scape Read More
  • Powered By CARB-X company Spero announces positive Phase 1 clinical data from their Potentiator Platform Read More
  • Powered By CARB-X company Visterra Closes $46.7 Million Series Financing to Advance Pipeline of Precision Antibody-Based Biological Medicines Read More
  • Powered By CARB-X company Entasis Receives Second CARB-X Award, Providing up to $10.1 Million for Development of Non-Beta-Lactam PBP Inhibitor Program Read More
  • Powered By CARB-X company Antabio Raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections Read More
  • Powered By CARB-X company Forge & Evotec Expand Strategic Alliance With Launch of BLACKSMITH Platform to Discover Novel Metalloenzyme Inhibitors Across Broad Therapeutic Areas Read More
  • Powered By CARB-X company Cidara Announces Pricing of $20M Private Placement of Common Stock Read More